Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Paola Fioretto & Angelo Avogaro. (2017) Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes. Expert Opinion on Pharmacotherapy 18:5, pages 517-527.
Read now
Read now
Articles from other publishers (26)
Michail Koutentakis, Jakub Kuciński, Damian Świeczkowski, Stanisław Surma, Krzysztof J. Filipiak & Aleksandra Gąsecka. (2023) The Ketogenic Effect of SGLT-2 Inhibitors—Beneficial or Harmful?. Journal of Cardiovascular Development and Disease 10:11, pages 465.
Crossref
Crossref
Habib Yaribeygi, Mina Maleki, Tannaz Jamialahmadi, Nikolay K. Shakhpazyan, Prashant Kesharwani & Amirhossein Sahebkar. (2023) Nanoparticles with SGLT2 inhibitory activity: Possible benefits and future. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 17:10, pages 102869.
Crossref
Crossref
Shubham Patil, Shital Bahadure & Sharvil Patil. (2023) Formulation of canagliflozin hemihydrate-loaded bilosomes for the treatment of Type-2 diabetes mellitus: In vitro, in vivo and in silico molecular docking studies. Journal of Drug Delivery Science and Technology 86, pages 104630.
Crossref
Crossref
Habib Yaribeygi, Mina Maleki, Thozhukat Sathyapalan, Tannaz Jamialahmadi & Amirhossein Sahebkar. (2023) Renal Effects of Empagliflozin in Patients with Type 2 Diabetes
Mellitus. Current Medicinal Chemistry 30:25, pages 2850-2863.
Crossref
Crossref
Habib Yaribeygi, Mina Maleki, Stephen L. Atkin, Prashant Kesharwani, Tannaz Jamialahmadi & Amirhossein Sahebkar. (2023) Anti‐inflammatory effects of sodium‐glucose cotransporter‐2 inhibitors in COVID‐19. IUBMB Life 75:8, pages 648-658.
Crossref
Crossref
Delal Dalga, Thomas Verissimo & Sophie de Seigneux. (2023) Gluconeogenesis in the kidney: in health and in chronic kidney disease. Clinical Kidney Journal 16:8, pages 1249-1257.
Crossref
Crossref
Habib Yaribeygi, Mina Maleki, Stephen L. Atkin, Tannaz Jamialahmadi & Amirhossein Sahebkar. (2023) SGLT2 inhibitors and autophagy in diabetes. Cell Biochemistry and Function 41:4, pages 392-398.
Crossref
Crossref
Munteanu Madalina Andreea, Swarnkar Surabhi, Popescu Razvan-Ionut, Ciobotaru Lucia, Nicolae Camelia, Tufanoiu Emil & Nanea Ioan Tiberiu. (2023) Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?. Medicina 59:4, pages 742.
Crossref
Crossref
Habib Yaribeygi, Mina Maleki, Alexandra E. Butler, Tannaz Jamialahmadi & Amirhossein Sahebkar. (2022) New insights into cellular links between sodium–glucose cotransporter‐2 inhibitors and ketogenesis. Journal of Cellular Biochemistry 123:12, pages 1879-1890.
Crossref
Crossref
Habib Yaribeygi, Mina Maleki, Željko Reiner, Tannaz Jamialahmadi & Amirhossein Sahebkar. (2022) Mechanistic View on the Effects of SGLT2 Inhibitors on Lipid Metabolism in Diabetic Milieu. Journal of Clinical Medicine 11:21, pages 6544.
Crossref
Crossref
Habib Yaribeygi, Mina Maleki, Alexandra E. Butler, Tannaz Jamialahmadi & Amirhossein Sahebkar. (2022) Sodium-Glucose Co-Transporter-2 Inhibitors and Epicardial Adiposity. European Journal of Pharmaceutical Sciences, pages 106322.
Crossref
Crossref
Habib Yaribeygi, Mina Maleki, Fatemeh Nasimi, Alexandra E. Butler, Tannaz Jamialahmadi & Amirhossein Sahebkar. (2022) Sodium‐glucose co‐transporter 2 inhibitors and hematopoiesis. Journal of Cellular Physiology 237:10, pages 3778-3787.
Crossref
Crossref
Rabia Salman Mahfooz, Muhammad Khuzzaim Khan, Hussam Al Hennawi & Anwar Khedr. (2022) SGLT-2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis: A Case Report and a Literature Review. Cureus.
Crossref
Crossref
Alexander E. Berezin & Alexander A. Berezin. (2022) Sodium-Glucose Co-transporter-2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Breakthrough in Improvement of Clinical Outcomes?. European Medical Journal.
Crossref
Crossref
Dilpreet Singh, Amrit Pal Singh, Drishtant Singh, Anup Kumar Kesavan, Ashok K. Tiwary & Neena Bedi. (2020) Polymeric Precipitation Inhibitor–Based Solid Supersaturable SMEDD Formulation of Canagliflozin: Improved Bioavailability and Anti-diabetic Activity. Journal of Pharmaceutical Innovation 16:2, pages 317-336.
Crossref
Crossref
Habib Yaribeygi, Milad Ashrafizadeh, Thozhukat Sathyapalan, Tannaz Jamialahmadi & Amirhossein Sahebkar. 2021. Natural Products and Human Diseases. Natural Products and Human Diseases
523
530
.
Theocharis Koufakis, Omar G. Mustafa, Ramzi A. Ajjan, Xavier Garcia‐Moll, Pantelis Zebekakis, George Dimitriadis & Kalliopi Kotsa. (2020) The use of sodium‐glucose co‐transporter 2 inhibitors in the inpatient setting: Is the risk worth taking?. Journal of Clinical Pharmacy and Therapeutics 45:5, pages 883-891.
Crossref
Crossref
Dilpreet Singh, Amrit Pal Singh, Drishtant Singh, Anup Kumar Kesavan, Saroj Arora, Ashok K. Tiwary & Neena Bedi. (2020) Enhanced oral bioavailability and anti-diabetic activity of canagliflozin through a spray dried lipid based oral delivery: a novel paradigm. DARU Journal of Pharmaceutical Sciences 28:1, pages 191-208.
Crossref
Crossref
Habib Yaribeygi, Stephen L. Atkin, Tannaz Jamialahmadi & Amirhossein Sahebkar. (2020) A Review on the Effects of New Anti-Diabetic Drugs on Platelet Function. Endocrine, Metabolic & Immune Disorders - Drug Targets 20:3, pages 328-334.
Crossref
Crossref
Habib Yaribeygi, Luis E. Simental-Mendía, Maciej Banach, Simona Bo & Amirhossein Sahebkar. (2019) The major molecular mechanisms mediating the renoprotective effects of SGLT2 inhibitors: An update. Biomedicine & Pharmacotherapy 120, pages 109526.
Crossref
Crossref
Habib Yaribeygi, Fadel Lhaf, Thozhukat Sathyapalan & Amirhossein Sahebkar. (2019) Effects of novel antidiabetes agents on apoptotic processes in diabetes and malignancy: Implications for lowering tissue damage. Life Sciences 231, pages 116538.
Crossref
Crossref
Ji‐Won Kim, Ye‐Jee Lee, Young‐Hye You, Min Kyong Moon, Kun‐Ho Yoon, Yu‐Bae Ahn & Seung‐Hyun Ko. (2018) Effect of sodium‐glucose cotransporter 2 inhibitor, empagliflozin, and α‐glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes. Journal of Cellular Biochemistry 120:5, pages 8534-8546.
Crossref
Crossref
Habib Yaribeygi, Stephen L. Atkin & Amirhossein Sahebkar. (2019) Mechanistic effects of SGLT2 inhibition on blood pressure in diabetes. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 13:2, pages 1679-1683.
Crossref
Crossref
Jaime Davidson, Sanjay Kalra, Vikram Singh, Mayuresh Fegade, Gursimran Singh & Amey Mane. (2017) Resolving the KgA1c paradox in the management of type 2 diabetes mellitus. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 11, pages S159-S168.
Crossref
Crossref
Atsushi Tanaka, Teruo Inoue, Masafumi Kitakaze, Jun-ichi Oyama, Masataka Sata, Isao Taguchi, Wataru Shimizu, Hirotaka Watada, Hirofumi Tomiyama, Junya Ako, Yasushi Sakata, Toshihisa Anzai, Masaaki Uematsu, Makoto Suzuki, Kazuo Eguchi, Akira Yamashina, Yoshihiko Saito, Yasunori Sato, Shinichiro Ueda, Toyoaki Murohara & Koichi Node. (2016) Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial. Cardiovascular Diabetology 15:1.
Crossref
Crossref
Gary Meininger, William Canovatchel, David Polidori & Norm Rosenthal. (2015) Canagliflozin for the treatment of adults with Type 2 diabetes. Diabetes Management 5:3, pages 183-201.
Crossref
Crossref